GlassScriptPhysician profile
Ahmed Abdelkader
NPI 1578912572
$3,158.30
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.20 · 2021: $105 · 2022: $961 · 2023: $1,489 · 2024: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,081.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $666.16 | 2021-2024 | Ubrelvy, Qulipta, Botox |
| Livanova USA, INC. | $330.20 | 2022-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Novartis Pharmaceuticals Corporation | $240.68 | 2022-2024 | |
| Supernus Pharmaceuticals, INC. | $222.48 | 2023-2024 | Qelbree |
| Kyowa Kirin, INC. | $122.51 | 2022-2024 | Nourianz |
| Neurocrine Biosciences, INC. | $105.04 | 2022-2024 | Ingrezza, Ongentys |
| Jazz Pharmaceuticals INC. | $99.60 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $96.52 | 2022-2023 | Austedo Xr, Austedo |
| Argenx US, INC. | $92.32 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Genentech USA, INC. | $85.86 | 2023-2024 | Ocrevus, Enspryng |
| Lilly USA, LLC | $81.81 | 2022-2023 | Amyvid, Emgality |
| Csl Behring | $75.84 | 2022-2024 | Hizentra |
| Ucb, INC. | $74.75 | 2023-2024 | Briviact |
| Amgen INC. | $74.14 | 2022-2023 | Aimovig |
| Avion Pharmaceuticals | $73.76 | 2022-2023 | Dhivy |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $68.63 | 2024 | Apokyn |
| Cala Health, INC. | $63.01 | 2023 | Cala Trio, Cala Kiq |
| Takeda Pharmaceuticals U.S.A., INC. | $46.38 | 2023-2024 | Hyqvia |
| Pfizer INC. | $45.04 | 2023 | |
| Lundbeck LLC | $43.92 | 2023 | Vyepti, Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $37.22 | 2022 | |
| Eisai INC. | $37.13 | 2023-2024 | |
| Impel Pharmaceuticals INC. | $35.39 | 2022-2023 | Trudhesa |
| Janssen Pharmaceuticals, INC | $32.34 | 2022 | |
| Neurelis, INC. | $31.15 | 2023 | Valtoco |
| Catalyst Pharmaceuticals, INC. | $29.50 | 2022 | |
| Sk Life Science, INC. | $26.39 | 2023 | |
| Biogen, INC. | $25.31 | 2019-2022 | |
| Corium, LLC | $23.08 | 2022 | |
| Xeris Pharmaceuticals, INC. | $21.68 | 2023 | Keveyis |
| Ge Healthcare | $19.63 | 2023 | |
| Acadia Pharmaceuticals INC | $19.38 | 2023 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $18.84 | 2023 | Ultomiris |
| Emd Serono, INC. | $18.15 | 2023 | Mavenclad |
| Acorda Therapeutics, INC | $16.74 | 2023 | Inbrija, Ampyra |
| Medtronic, INC. | $16.46 | 2022 | |
| Celgene Corporation | $16.12 | 2023 | |
| Alnylam Pharmaceuticals INC. | $13.28 | 2022 | |
| Allergan, INC. | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Abdelkader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.